In this study, we compared expression levels of CXCR2P1 in different groups from different public databases, validated the potential of CXCR2P1 as a predictor of prognosis in gastric cancer patients receiving PD-1 inhibitors. This evidence concerns the gene PDCD1 and gastric cancer.